BNP Paribas Downgrades Sanofi (SNY) with ‘Unlikely Near-Term Rerating' [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Sanofi (NASDAQ:SNY) is a healthcare biopharmaceutical company that engages in the research, development, manufacture, and marketing of therapeutic solutions. On April 20, BNP Paribas analyst Peter Verdult downgraded Sanofi (NASDAQ:SNY) from ‘Outperform' to ‘Neutral', while assigning the stock a price target of $50. The firm cited its revised pipeline assumptions for the downgrade, noting that a “near-term rerating story is unlikely”. On the other hand, Citi analyst Graham Parry turned slightly more bullish on Sanofi (NASDAQ:SNY) earlier on April 13, raising the firm's price target on the stock from €80 to €82 ( read more details here Sanofi (NASDAQ:SNY) projects its sales to grow by a high single-digit percentage in FY 2026, with business EPS surging slightly faster than sales. The company expects this profitable growth to continue for at least five years. Additionally, Sanofi plans to execute a share buyback program of €1B this year. The strong guidance comes despite Sanofi
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapsesGlobeNewswire
- Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments [Yahoo! Finance]Yahoo! Finance
- ???????????(ATV)?????????????????(UTV)??:???????????? [CNET News]CNET News
- Sanofi Q1 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- How The Sanofi (ENXTPA:SAN) Narrative Is Shifting After Valuation Reset And Pipeline Updates [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 4/23/26 - Form 6-K
- 4/15/26 - Form 6-K
- 4/10/26 - Form SCHEDULE
- SNY's page on the SEC website